Taking Mounjaro with Gallstones: What the Clinical Guidance Says

What the Mounjaro clinical programme found about gallbladder problems

The SURMOUNT trials (involving thousands of adults treated with tirzepatide over 72 weeks) reported gallbladder-related events, including cholelithiasis (gallstone formation) and cholecystitis (gallbladder inflammation), as adverse effects at a rate that tracks with the degree of weight loss achieved. This is not unique to tirzepatide. The same pattern appears across GLP-1 receptor agonist medicines, and NICE's appraisal of tirzepatide (NICE TA1026) acknowledges the gallbladder findings within its overall assessment of the benefit-risk profile. The mechanism most researchers point to is straightforward: lose weight quickly, and bile becomes more saturated with cholesterol, creating conditions in which stones can form. If you want a deeper look at the relationship between this medicine and gallbladder health specifically, our page on Mounjaro and gallstones brings together the clinical evidence in one place. Tirzepatide also slows gastric emptying, which affects the rhythmic contraction of the gallbladder that normally prevents bile from sitting still for too long. Neither of these facts means tirzepatide is off the table if you have a gallstone history. They do mean the prescriber needs to know about it. You can read more about how this medicine works mechanically on our tirzepatide overview.

Does an existing gallstone diagnosis rule out treatment?

Not automatically, but context matters enormously. The Mounjaro SmPC, published on the electronic medicines compendium, lists gallbladder disorders under adverse reactions and notes that prescribers should use caution where there is pre-existing gallbladder disease. The relevant question is whether your gallstones are currently causing symptoms (biliary colic, blocked ducts, ongoing inflammation) or whether they are silent stones found incidentally on a scan. Symptomatic gallbladder disease that has not been treated is a more pressing concern, because the combination of GLP-1-related slowing of bile flow and weight-loss-driven changes to bile composition could worsen an already irritable gallbladder. Silent gallstones in someone with no recent episodes are a different risk profile altogether. This is exactly the kind of nuance a prescriber weighs during consultation, it cannot be resolved by a checklist. If you want to understand what the assessment process looks like, our page on clinical eligibility with gallstone history goes into more detail.

For people who have previously had their gallbladder removed (cholecystectomy), the picture shifts again. Without a gallbladder, stone formation is obviously no longer a risk, though bile-related digestive symptoms can still occur with rapid weight loss or GLP-1 treatment, and your prescriber will want to know your surgical history. Our guidance on taking Mounjaro explains what information to have ready before and during treatment, including your relevant medical history.

Symptoms to take seriously during treatment

This is the practical section to read carefully. Gallbladder pain and pancreatitis can produce overlapping symptoms, and both are flagged in the safety data for GLP-1 medicines. The NHS patient information for tirzepatide (NHS: tirzepatide) advises seeking urgent medical help for severe abdominal pain that does not ease, particularly if it spreads to the back, or is accompanied by fever, chills, yellowing of the skin or eyes (jaundice), or very dark urine. These can indicate a stone blocking the bile duct, acute cholecystitis, or pancreatitis, all of which need same-day clinical assessment, not a wait-and-see approach. On a practical note: some people on tirzepatide find their appetite changes enough that they eat less fat, which can ironically reduce gallbladder contraction frequency, another reason regular clinical check-ins matter. Keep your prescriber's contact details where you can find them quickly, alongside your pen in the fridge door. If you have any concerns about specific symptoms between reviews, the contact page has details for our aftercare team, available seven days a week.

Minimising gallbladder risk during tirzepatide treatment

The evidence base for gallstone prevention during GLP-1 treatment is still developing, but the consistent clinical advice centres on gradual, steady weight loss rather than very rapid early loss, adequate hydration, and not skipping meals entirely, a completely empty gut means the gallbladder rarely squeezes out its bile, letting it concentrate. The titration schedule built into Mounjaro (starting at a low dose and increasing slowly over weeks under prescriber supervision) is partly designed with tolerability in mind, and that same gradual approach is thought to reduce the sharpness of early weight-loss-related gallbladder stress compared with very aggressive calorie restriction. Our page on how to prevent gallstones on Mounjaro covers the dietary and lifestyle detail more fully, and if you want to go further into the practical steps you can take day to day, we also have a dedicated guide on how to avoid gallstones on Mounjaro that works through the habits and choices that can help reduce your risk during treatment. For anyone weighing up private treatment options, the treatment overview sets out what a consultation with our prescribers involves. A history of gallstones will be part of that conversation, openly and without it being a reason to rush to a decision either way.